DARVON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Darvon, and when can generic versions of Darvon launch?
Darvon is a drug marketed by Xanodyne Pharm and Aaipharma Llc and is included in six NDAs.
The generic ingredient in DARVON is aspirin; propoxyphene napsylate. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; propoxyphene napsylate profile page.
Summary for DARVON
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 42 |
Patent Applications: | 4,253 |
Formulation / Manufacturing: | see details |
DailyMed Link: | DARVON at DailyMed |
US Patents and Regulatory Information for DARVON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xanodyne Pharm | DARVON | propoxyphene hydrochloride | CAPSULE;ORAL | 010997-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Xanodyne Pharm | DARVON-N | propoxyphene napsylate | TABLET;ORAL | 016862-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Xanodyne Pharm | DARVON COMPOUND-65 | aspirin; caffeine; propoxyphene hydrochloride | CAPSULE;ORAL | 010996-007 | Mar 8, 1983 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |